Odyssey Therapeutics has priced its upsized initial public offering at $18 per share for 15.5 million shares, for gross proceeds of about $304 million, the company said late Thursday.
Underwriters have a 30-day option to purchase up to an additional 2.3 million shares.
The shares are expected to begin trading on Nasdaq on Friday, under the ticker, "ODTX."
The IPO expected to close on Monday, it added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.